US › Healthcare

TG Therapeutics Inc (TGTX)

US · Healthcare · Biotechnology

$48.73+5.56%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$204.9M
Revenue YoY
+69.6%
Net profit
$19.8M
Profit YoY
+290.8%
EPS
$0.18
EPS estimate
$0.28
Net margin
9.7%

EPS came in at 0.18 against a street estimate of 0.28 — a miss of 35.7%.

Key statistics

Market cap
$7.96B
P/E
18.2
Forward P/E
55.2
P/B
13.66
Book value
$4.11
EPS (TTM)
$2.86
52-week high
$59.30
52-week low
$25.28
50-day MA
$49.92
200-day MA
$36.68
Beta
1.60

Analyst view

Analysts rate TG Therapeutics Inc a buy (7 buy, 1 hold, 1 sell out of 9) with an average price target of $68.43.

Shareholding

Insiders
7.47%
Institutions
70.32%

Largest institutional holders

FundStake
BlackRock Inc14.54%
State Street Corp5.65%
Vanguard Portfolio Management, LLC5.40%
Vanguard Capital Management, LLC4.31%
Soleus Capital Management, L.P.2.63%
Geode Capital Management, LLC2.29%
ClearBridge Advisors, LLC2.10%
Congress Asset Management Company, LLP1.70%

Recent filings & reports

DocumentDate
Shareholder vote results · Q2 20262026-06-12
Company announcement · Q2 20262026-06-03
Company announcement · Q2 20262026-05-27
Quarterly report · Q1 20262026-05-06
Results announced · Q2 20262026-05-06
Proxy statement · Q2 20262026-04-30
Annual report FY20252026-02-27
Quarterly report · Q3 20252025-11-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for TG Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.